Last reviewed · How we verify
NCT03923855
Clinical Evaluation of the BTL-899 Device for Non-invasive Lipolysis on Human Fat Tissue
NA trial testing BTL-899 in Improvement of Abdomen Appearance in 8 participants. Completed in 7 October 2019.
17 September 2019
Quick facts
| Lead sponsor | BTL Industries Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 1 May 2019 |
| Primary completion | 17 September 2019 |
| Estimated completion | 7 October 2019 |
| Sites | 1 location across Bulgaria |
Drugs / interventions tested
- BTL-899
Conditions studied
- Improvement of Abdomen Appearance — all drugs for Improvement of Abdomen Appearance →
Sponsor
BTL Industries Ltd. — full company profile →
Who can join
Adults 21 to 60, any sex, with Improvement of Abdomen Appearance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The subjects will be enrolled and assigned to a single study group. They will be required to complete two treatment visits and come for a biopsy procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03923855
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BTL-899
Trials testing the same drug.
- NCT05540080 — Non-invasive Lipolysis and Improvement of Muscle Tone in Lateral Abdomen · NA · completed
- NCT05713864 — Combination Treatment With BTL-899 and HPM-6000UF Devices II · NA · completed
- NCT05139745 — Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue · NA · completed
- NCT04596228 — Non-invasive Lipolysis and Improvement of Muscle Tone in Inner Thighs · NA · completed
- NCT04643275 — Effect of BTL-899 Device for Non-invasive Lipolysis on Human Upper Arms · NA · completed
Other BTL Industries Ltd. trials
Trials by the same sponsor.
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07179224 — EEG Changes After rTMS Stimulation · NA · completed
- NCT07024550 — Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway · NA · active not recruiting
- NCT07027657 — EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03923855 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BTL Industries Ltd.
- Last refreshed: 20 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03923855.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing